Patent · US Expired

Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron

US6649183B2 · kind B2 · utility

21Cited by

36References

16Claims

0Family size

Assignee

Sepracor, Inc. · US

Inventors

Paul Rubin · Sudbury, US
Timothy J. Barberich · Concord, US

Key dates

Filing date	Nov 1, 2001
Grant date	Nov 18, 2003
Priority date	—
Expiry date	Nov 21, 2021

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.